Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Other financing activities (2023 - 2025)

Kura Oncology (KURA) has disclosed Other financing activities for 3 consecutive years, with $515000.0 as the latest value for Q2 2025.

  • Quarterly Other financing activities fell 83.06% to $515000.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $3.7 million through Jun 2025, down 39.98% year-over-year, with the annual reading at $1.8 million for FY2025, 79.16% down from the prior year.
  • Other financing activities for Q2 2025 was $515000.0 at Kura Oncology, up from $143000.0 in the prior quarter.
  • The five-year high for Other financing activities was $3.0 million in Q2 2024, with the low at $84000.0 in Q3 2023.
  • Average Other financing activities over 3 years is $1.2 million, with a median of $661000.0 recorded in 2024.
  • The sharpest move saw Other financing activities surged 2521.43% in 2024, then crashed 94.4% in 2025.
  • Over 3 years, Other financing activities stood at $84000.0 in 2023, then surged by 860.71% to $807000.0 in 2024, then plummeted by 36.18% to $515000.0 in 2025.
  • According to Business Quant data, Other financing activities over the past three periods came in at $515000.0, $143000.0, and $807000.0 for Q2 2025, Q1 2025, and Q4 2024 respectively.